Puma Biotechnology, INC 10-Q quarterly reports

Puma Biotechnology's Q2 2026 results show a modest increase in total revenue driven by product sales, alongside a significant rise in research and development expenses.

Puma Biotechnology reported a slight revenue decrease in Q1 2026, with product revenue at $42.0 million, while research and development expenses surged due to increased alisertib study activity.

Puma Biotechnology, Inc. amended its Note Purchase Agreement, extending a key equity issuance deadline while reporting a decrease in total revenue for the third quarter and first nine months of 2025.

Puma Biotechnology, Inc. reported a significant turnaround to net income and increased revenue for the second quarter and first half of 2025, driven by strong NERLYNX sales and reduced operating expenses, despite ongoing patent litigation challenges.

Puma Biotechnology, Inc. filed an amendment to its first-quarter 2025 report to disclose an inadvertently omitted Rule 10b5-1 trading arrangement for a board member and include updated certifications.

Puma Biotechnology announces a profitable first quarter in 2025, with net income driven by increased product revenue and strategic expense management.

Puma Biotechnology's Q3 2024 results show a significant increase in total revenue, primarily driven by a surge in royalty revenue and a modest increase in product sales.

Puma Biotechnology's Q2 2024 results show a decrease in revenue compared to the same period last year, alongside ongoing legal proceedings and strategic developments.

Puma Biotechnology's first quarter of 2024 saw a decrease in revenue and a net loss, while the company continues to navigate legal challenges and manage its debt obligations.